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Abstract
Background: Analysis of somatic mutations provides insight into the mutational processes that have shaped the
cancer genome, but such analysis currently requires large cohorts. We develop deconstructSigs, which allows the
identification of mutational signatures within a single tumor sample.
Results: Application of deconstructSigs identifies samples with DNA repair deficiencies and reveals distinct and
dynamic mutational processes molding the cancer genome in esophageal adenocarcinoma compared to
squamous cell carcinomas.
Conclusions: deconstructSigs confers the ability to define mutational processes driven by environmental exposures,
DNA repair abnormalities, and mutagenic processes in individual tumors with implications for precision cancer
medicine.
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Background
The set of somatic mutations observed in a tumor reflects
the varied mutational processes that have been active dur-
ing its life history, providing insights into the routes taken
to carcinogenesis. Exogenous mutagens, such as tobacco
smoke and ultraviolet light, and endogenous processes,
such as APOBEC enzymatic family functional activity or
DNA mismatch repair deficiency, result in characteristic
patterns of mutation [1, 2]. Thus, through studying the full
landscape of mutations present in a tumor and identifying
the genomic footprint of mutational signatures that have
contributed to them, processes molding the cancer
genome during evolution can be revealed and individual
therapeutic strategies considered if distinct DNA repair
defects are identified [3]. Analysis of mutational signatures
has the potential to reveal previously unknown mutagens
and occult environmental exposures, such as herbal sup-
plements containing aristolochic acid [3].
Recently, Alexandrov and colleagues developed an al-
gorithm using non-negative matrix factorization (NMF)
and model selection to extract the signatures of muta-
tional processes present in a catalog of cancer genomes
[4]. Each extracted signature is characterized by the frac-
tion of mutations found in each of the 96 trinucleotide
contexts. Additional mutation features such as the pres-
ence of indels, dinucleotide mutations, or transcriptional
strand bias could also be incorporated into the definition
of a mutational signature.
Their published Wellcome Trust Sanger Institute
(WTSI) Mutational Signature Framework offers an elegant
approach to first identify the signatures of mutational pro-
cesses present in a set of tumor samples and then apply
those signatures to the samples to determine the contribu-
tion of each mutational process to each individual sample.
However, in order to accurately deconvolute signatures,
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the number of tumor samples available must be suffi-
ciently large. In simulations, Alexandrov et al. found that
at least 200 whole genome samples were required to de-
termine the signatures of 20 mutational processes [5].
With exome sequencing covering only ~1 % of the human
genome, resulting in fewer mutations identified, they esti-
mated that it would take thousands of samples to extract
the majority of mutational processes that have been func-
tional during tumor life histories.
Using their framework, Alexandrov et al. analyzed
approximately five million mutations from over 7000
cancer genomes and exomes to identify a set of 21 sig-
natures found to be present across 30 tumor types [4].
About half of these signatures could be attributed to
known mutational processes, such as tobacco smoke,
exposure to ultraviolet light, activity of the APOBEC
family of cytidine deaminases, DNA mismatch repair
deficiency, or mutations in POLE. Many signatures,
corresponding to the activity of both known and unknown
mutational processes, were found across multiple tumor
types. Due to the ubiquitous nature of many of the signa-
tures found, there has been interest in quantifying their
presence and prevalence in additional tumor samples.
However, this is not always possible under the current
mutational framework.
In order to address this challenge, we present a method
to determine the contributions of each mutational process
from a set of published signatures in a single tumor
sample.
Implementation
Overview of the software
The deconstructSigs approach determines the linear
combination of pre-defined signatures that most ac-
curately reconstructs the mutational profile of a single
tumor sample. It uses a multiple linear regression model
with the caveat that any coefficient must be greater
than 0, as negative contributions make no biological
sense. The deconstructSigs package is an extension for
R, a free programming language and software environ-
ment widely used for statistical computing and graphics.
This package relies on the Bioconductor library BS.geno-
me.Hsapiens.UCSC.hg19 [6] to acquire mutational context
information. It also uses reshape2 [7] for plotting. The
R package is publicly available on the CRAN webpage:
https://cran.r-project.org/. A detailed README file is also
available complete with examples of how to use the
package.
Basic usage
The most basic initial input to the deconstructSigs pack-
age consists of a data frame containing the mutational
data for a tumor sample set. This structure must contain
the genomic position and base change for each mutation,
as well as a sample identifier. Using the command “mut.-
to.sigs.input”, as shown below, the mutational data for one
to many tumors is converted to an n-row and 96-columns
data frame where n is the number of unique samples
present.
sigs.input < - mut.to.sigs.input(mut.ref = sample.mut.ref,
sample.id = "Sample", chr = "chr", pos = "pos", ref = "ref",
alt = "alt")
The input data frame T is generated by calculating the
fraction of mutations found in each of the possible 96
trinucleotide contexts for each tumor sample. By default,
no additional normalization is performed. However, when
T contains only the counts of each mutation in each trinu-
cleotide context, the user may choose to set an additional
parameter to normalize by the number of times each tri-
nucleotide context is observed in the region sequenced.
Trinucleotide counts for exome and genome data are pro-
vided in the package for this normalization. Alternatively,
a user can also generate their own T data frame to use as
input into deconstructSigs. A signatures matrix S of k
rows and 96 columns is also defined, either calculated
from published data [4] or provided by the user, where k is
the number of supplied signatures. S consists of the frac-
tion of times a mutation is seen in each of the 96 trinucle-
otide contexts for each signature k. Given these two
inputs, T and S, deconstructSigs computes weights Wi (for
each signature i from 1 to k) such that each signature has
a weight. These weights are determined such that a recon-
structed tumor sample matrix R, which is computed as T-
(SW), minimizes a given error threshold e.
This step is called with the function “whichSignatures”
as shown below.
output.sigs = whichSignatures(tumor.ref = randomly.
generated.tumors, signatures.ref = signatures.nature2013,
sample.id = "1")
To determine the weights W that will best recreate T,
an iterative approach is taken. First, we exclude any sig-
natures containing a single trinucleotide context making
up more than 20 % of the signature definition which is
not present in T. This is done to account for the fact
that some signatures are almost entirely characterized by
mutations in specific trinucleotide contexts, and thus,
without mutations found in those contexts, it is unlikely
that that signature is active. From the remaining signa-
tures, an initial mutational signature is chosen that most
closely reflects the mutational profile of the given tumor
sample by minimizing the sum-squared error (SSE) be-
tween the mutational profile of the tumor sample T and
the mutational signature Si. The weights, W, are initial-
ized such that the initial signature chosen, Si, is the only
signature contributing to the reconstructed tumor muta-
tional profile, thus being assigned a normalized weight of
1. A forward selection process subsequently determines,
for each signature, the optimal weight that minimizes the
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SSE between the given tumor sample and the recon-
structed tumor profile. From this set of possible
weights, the weight corresponding to the signature that
results in the overall lowest SSE is provided in W. This
iterative process repeats until the difference between
the SSE before and after the alteration of the weights
matrix is less than an empirically chosen error thresh-
old of 0.001.
Finally, the weights W are normalized between 0 and 1
and any signature with Wi < 6 % is excluded. This 6 %
threshold was chosen by randomly generating tumors in
silico whose mutational profiles were perturbed to be
distant from the ideal theoretical sample. Initially, a set
of 500 tumors representing a random combination of up
to 10 of the published mutational signatures [4] was
simulated. Because a tumor will never reflect a perfect
combination of mutational signatures, these simulated
tumors were perturbed by changing the calculated value
at each trinucleotide context by up to ±5 %. These per-
turbed tumor samples were analyzed with deconstructSigs
and the calculated weights were compared with the theor-
etical weights used to generate the set of simulated tumors.
This analysis revealed that false positives had weights Wi
routinely less than 6 % (Figure S1a in Additional file 1).
Additionally, this 6 % cutoff only resulted in 38 instances
where a signature was incorrectly excluded for a false nega-
tive rate of 1.4 % (Figure S1b in Additional file 1). A recon-
structed tumor mutational profile R based on these final
weights is determined as described above. A schematic of
our deconstructSigs approach is outlined in Fig. 1a. To
visualize the output, two plotting functions are available.
The first compares the reconstructed tumor mutational
profile with the original input tumor profile and is called
using “plotSignatures”. Figure 1b shows an example of the
generated plot. The second is a pie chart that shows the
weights of each signature assigned in the sample and is
called with “makePie”. They both use the output list given
by “whichSignatures” as input.
Results
Comparison with WTSI Mutational Signature Framework
To investigate how deconstructSigs compares with the
results generated by a user running the published WTSI
Mutational Signature Framework on a new set of samples,
we analyzed available data from The Cancer Genome
Atlas (TCGA) on bladder urothelial carcinoma (BLCA),
breast invasive carcinoma (BRCA), colon adenocarcinoma
(COAD), glioblastoma multiforme (GBM), head and neck
squamous cell carcinoma (HNSC), lung adenocarcinoma
(LUAD), lung squamous cell carcinoma (LUSC), and
skin cutaneous melanoma (SKCM) cancers (https://
tcga-data.nci.nih.gov/tcga). The specific mutation files
for these tumor types are detailed in Additional file 2.
We first implemented the WTSI Mutational Signature
Framework to independently extract signatures present
in each cancer type. Twenty-six mutational signatures
were extracted using the WTSI Mutational Signature
Framework as described in McGranahan et al. [8]. For
some TCGA cancer types, we found that the number of
available samples was too low to achieve the resolution
necessary to extract all the signatures previously associ-
ated with that cancer type. Reassuringly, the majority of
signatures (20/26) extracted matched in profile those
published by Alexandrov et al. [4] and were consistent
with those original signatures. The age related signatures,
1A and 1B, were considered together as one signature.
Two of the discordant signatures appeared to be a mix of
two or three of the original signatures, highlighting again
the importance of large sample numbers for accurately
deconvoluting novel mutational signatures.
All the newly extracted signatures were then used, as
S, with deconstructSigs to analyze the same cohort of
samples. This allowed for a direct comparison between
the weighted proportions produced by the WTSI Muta-
tional Signature Framework and those inferred with
deconstructSigs. For every signature present in a given
sample, we observed a statistically significant correlation
(Additional file 3) between the contributions of that sig-
nature in the two independent methods (Fig. 2). These
data indicated that we could consistently identify the sig-
natures present in an individual tumor sample using
deconstructSigs.
The SSE between the reconstructed mutational profile
and the observed one, obtained by calculating the frac-
tion of mutations present in each trinucleotide context,
was consistently similar between the two approaches
(Figure S2a in Additional file 4). The SSE calculated from
both methods was higher in samples with a lower muta-
tion count (Figure S2b in Additional file 4), highlighting
the importance of having a sufficient number of mutations
to identify and assign signatures characterized by 96-
substitution classifications. This is of particular import-
ance when the profile of the mutational signature is flat
or without a strong peak at any of the trinucleotide
contexts, as in these instances the mutational process
could affect a greater number of trinucleotide contexts
and a full profile would only be observed with sufficient
mutations. Consequently, deconstructSigs warns the
user if a sample contains fewer than 50 mutations.
Additionally, the analysis uncovered a number of false
positive mutational signatures that arise using the WTSI
framework, whereby samples were erroneously classified
as harboring a mutational signature. For instance, in a
colorectal carcinoma (TCGA-D5-6931) the WTSI Muta-
tional Signature Framework determined 20.4 % of the
mutational signature present was associated with a POLE
hyper-mutator phenotype. Nevertheless, visual inspection
of the mutational profile of this tumor did not reveal the
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Fig. 1 deconstructSigs workflow and output. a Given an input tumor profile and reference input signatures, deconstructSigs iteratively infers the
weighted contributions of each reference signature until an empirically chosen error threshold is reached. b Example of the plot generated by
the command ‘plotSignatures’. The top panel is the tumor mutational profile displaying the fraction of mutations found in each trinucleotide
context, the middle panel is the reconstructed mutational profile created by multiplying the calculated weights by the signatures, and the bottom
panel is the error between the tumor mutational profile and reconstructed mutational profile, with SSE annotated
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presence of a POLE-associated signature and no evidence
existed for the somatic exonuclease domain mutations in
POLE that produce this specific pattern of predominantly
C > A mutations in a TpCpT context and C > T mutations
in a TpCpG context (Fig. 3a).
To further explore the presence of both false positive
and false negative mutational signatures using the WTSI
mutational framework, we also repeated our analysis,
expanding the signature space in which deconstructSigs
could search. Thus, instead of using the newly extracted
signatures by the WTSI mutational signature framework
alone, we allowed deconstructSigs to use any of the ori-
ginal signatures [4]. For this analysis, we excluded any
cancer types where the number of samples was originally
too low such that extracting signatures using the WTSI
Mutational Signature Framework method resulted in sig-
natures that were a mixture of the published ones. In
these instances a comparison between these ‘mixed’ sig-
natures and the ability of deconstructSigs to identify
them using the published signatures as a reference set
could not be fairly made. The cancer types excluded
were BLCA, COAD, GBM, and SKCM.
Re-extracted signatures through a separate iteration of
the WTSI Mutational Signature Framework on new
samples are always slightly different from the originally
published ones, particularly when fewer samples are
used for extraction as each signature is less well re-
solved. Thus, we did not expect to see a perfect correl-
ation between the weights assigned by deconstructSigs
using the original signatures as reference and the contri-
butions found in our initial run of the WTSI Mutational
Signature Framework (as was observed in Fig. 2). However,
when we compared the weights assigned by deconstruct-
Sigs and the contributions by the WTSI Mutational Signa-
ture Framework, we saw a strong positive and statistically
significant correlation for all signatures except signature 3
and signature 5 (Additional files 5 and 6). Notably, sig-
natures 3 and 5 are characterized by relatively flat mu-
tational profiles, exhibiting few distinguishing patterns
of trinucleotide context.
Expanding the set of signatures also allowed us to
identify outlier samples that appear to harbor a different
set of mutational signatures compared with the rest of
the cancer type or sample set they were analyzed with.
Contributions can be missed by the WTSI Mutational
Signature Framework if the signature is not prevalent
enough in the sample set to be extracted as a separate
entity. For instance, the LUAD sample TCGA-67-6215
has clear indications of signature 17 activity, a signature
of unknown etiology (Fig. 3b). However, since signature
17 was not one of the signatures extracted through the
implementation of the WTSI Mutational Signature
Framework, it could not be identified as contributing
to the observed mutational spectrum. Likewise, the
deconstructSigs package assigned substantial contri-
butions from the signature associated with DNA mis-
match (MMR) repair deficiency (signature 6) to the
BRCA samples TCGA-A8-A08F, TCGA-A8-A09Z, and
TCGA-AN-A0AK (Fig. 3c), but signature 6 was not
extracted through the implementation of the WTSI
Mutational Signature Framework, nor was it associ-
ated with breast cancer in the work published in 2013
Fig. 2 Comparison of signature contributions identified with deconstructSigs and WTSI Mutational Signature Framework. Scatterplots represent
the relationship between the weighted proportions calculated using the WTSI Mutational Signature Framework method on a set of TCGA tumors
and those inferred with deconstructSigs from the same set of patients. Each point plotted represents the weights assigned by both methods to
one signature detected in a patient
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Fig. 3 (See legend on next page.)
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[4]. In two of these tumors, TCGA-A8-A09Z and
TCGA-AN-A0AK, mutations in mismatch repair genes
were evident (https://tcga-data.nci.nih.gov/tcga/). There
was an MLH1 nonstop mutation in TCGA-A8-A09Z and
separate MLH1 missense and splice site mutations, as well
as an MSH6 frameshift mutation in TCGA-AN-A0AK.
Additionally, TCGA-A8-A09Z had a total of 1438 muta-
tions with 253 small insertions or deletions and TCGA-
AN-A0AK had a total of 1317 mutations with 352 small
insertions or deletions, both indicative of a microsatellite
instability high (MSIH) phenotype. The median number
of mutations from the BRCA TCGA cohort is 38 and
median number of insertions or deletions is 4.
Taken together, these results highlight the power of
analyzing tumors on an individual basis, allowing the de-
tection of mutational processes only active in a small
subset of the samples considered.
Identifying signatures in multi-region sequencing data
To further determine the performance of deconstructSigs,
we examined a cohort of 19 tumors collected from six pa-
tients diagnosed with either LUAD or LUSC, with one
tumor exhibiting an adenosquamous histological subtype.
Multi-region whole-exome and/or genome sequencing
was previously performed in these patients as described in
de Bruin et al. [9] with mutations temporally dissected
into trunk and branch mutations and the fraction of muta-
tions occurring in each of the six possible base substitu-
tion classes previously established [9]. Given the limited
number of tumor samples, the mutational catalogues from
these samples were not amenable to a de novo analysis
with the WTSI Mutational Signature Framework. We
therefore used deconstructSigs with the 23 original sig-
natures [4] to establish the contribution of individual
mutational signatures to the samples.
Whilst our original analysis utilized C > A mutations
as a surrogate measure of a smoking signature resulting
from tobacco exposure, deconstructSigs enabled us to
refine this analysis. This new analysis allowed us to deter-
mine the specific contribution of signature 4, known to be
associated with the number of smoking pack years [1, 4],
rather than the more general C > A mutation class. Con-
sistent with the previous analysis, we observed that the
smoking associated signature (signature 4) was present at
a higher fraction in the clonal mutations originating in the
tumor trunk and found at a lower fraction in the subclonal
mutations in the tumor branches (Fig. 4a). Indeed, in three
of the five patients analyzed (L001, L004, and L008), the
smoking signature was not assigned at all in the branches.
We next investigated the assigned weights of the APO-
BEC-associated signatures (signature 2 and signature 13)
and found that in the LUAD subtypes, the signature was
more pronounced in the branches than in the trunk
(Fig. 4b), consistent with our published observations.
These results demonstrate the utility of deconstruct-
Sigs leveraging well-established signatures to determine
the contribution of given mutational signatures to indi-
vidual tumors, refining mutational processes present in
cancer subclones.
Exploring signatures in esophageal carcinoma
To further determine the utility of deconstructSigs, we
applied our framework to each esophageal tumor (ESCA),
both adenocarcinomas and squamous cell carcinomas
from TCGA (https://tcga-data.nci.nih.gov/tcga). The
mutation files were obtained from Broad Institute MAF
dashboard (https://confluence.broadinstitute.org/display/
GDAC/MAF+Dashboard). Notably, in the original publi-
cation by Alexandrov et al. [4], these two cancer types
were considered in aggregate given the limited number of
samples available. Using deconstructSigs, it was possible
to directly compare esophageal tumors originating from
these different cell types. In addition, in order to shed light
on both the prevalence of mutational processes and their
dynamics during tumor evolution, we also applied the
deconstructSigs package to temporally dissected mutations
(Additional file 7), according to published methods [8]. This
allowed us to identify different mutational processes
contributing to early and late/subclonal mutations.
In total, across these 169 esophageal tumors, eight
mutational signatures were evident, many of which were
found to contribute to varying degrees during different
periods of the disease course. The most prevalent signa-
ture in both esophageal adenocarcinoma and squamous
cell carcinomas, signature 1A, which likely reflects spon-
taneous deamination of methylated cytosines, was
(See figure on previous page.)
Fig. 3 Specific TCGA patient examples. Comparison of tumor mutational profiles and reconstructed profiles output from deconstructSigs and
WTSI Mutational Signature Framework. The reconstructed tumor profiles generated by using the signature weights assigned by the deconstructSigs
method and the WTSI Mutational Signature Framework method are given for three tumor samples. a A signature associated with POLE hypermutation,
signature 10, was identified in TCGA patient TCGA-D5-6931 using the WTSI Mutational Signature Framework (signature weight = 0.204) but not with
deconstructSigs. However, a POLE exonuclease domain mutation was not observed in this patient. b The mutational profile of patient TCGA-67-6215
showed activity of Signature 17 but as this signature was not considered a possible signature extracted in the first step of the WTSI Mutational
Signature Framework output, it was only called with deconstructSigs (signature weight = 0.634). c A signature associated with DNA mismatch
repair deficiency, signature 6, was identified by deconstructSigs (signature weight = 0.481) in patient TCGA-AN-A0AK but was not identified by
the WTSI Mutational Signature Framework. An MSH6 frameshift mutation was identified in TCGA-AN-A0AK indicating the DNA mismatch repair
deficiency signature identified is unlikely to be spurious
Rosenthal et al. Genome Biology  (2016) 17:31 Page 7 of 11
detected in almost all ESCA tumors studied. Interest-
ingly, this signature was found to contribute significantly
more to early mutations compared with late mutations
in esophageal squamous cell carcinoma but not in
esophageal adenocarcinoma (ESCA squamous, p value =
0.006; ESCA adeno, p value = 0.716; Fig. 5a).
Signature 2, likely reflecting APOBEC-mediated muta-
genesis, was identified as contributing significantly more in
squamous cell compared with adenocarcinoma esophageal
cancers (p value = 0.01). Further, in squamous cell tumors,
APOBEC-mediated mutagenesis was found frequently
to be a late event, reflecting similar findings in lung
adenocarcinomas, head-and-neck tumors, and estrogen
receptor-negative breast cancers [8] (p value = 0.03; Fig. 5a).
Conversely, no significant trend was observed in esophageal
adenocarcinomas.
Another clear difference between esophageal tumors
of these two cell types was the presence of signature 17,
A
B
Fig. 4 Temporal dissection of mutational processes. Mutations called from a cohort of five LUAD (circles) and LUSC (triangles) patients with multi-region
sequencing were temporally dissected into trunk and branch mutations, described previously in [9]. One patient (L002) had a tumor exhibiting
an adenosquamous histological subtype, with separate regions being of different histology. For each patient, the fraction of contribution of
signatures associated with smoking (a) and APOBEC activity (b) was determined in the trunk and branch mutations. The smoking signature
was seen at higher fractions in the trunk mutations (blue) than the branch mutations (red), whereas the signature of APOBEC activity was seen
to contribute more to the LUAD branch mutations than LUAD trunk mutations or LUSC trunk or branch mutations
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Fig. 5 (See legend on next page.)
Rosenthal et al. Genome Biology  (2016) 17:31 Page 9 of 11
a signature of unknown etiology, exclusively in adeno-
carcinomas. Indeed, over 50 % of esophageal adenocar-
cinomas were found to exhibit an enrichment for T > G
and T > C mutations at CpTpT sites. The majority of
these tumors (65 %) showed a tendency for signature 17
to be an early event, often being replaced by signature
1A. For example, in one such tumor (TCGA-2H-A9GR),
early mutations were almost exclusively characterized as
signature 17 (90.4 %), while later arising mutations were
characterized by an increase in signature 1A at the ex-
pense of signature 17. These data corroborate recent
findings using multi-region sequencing [10]. Neverthe-
less, we also identified a subset of esophageal adenocar-
cinomas in which signature 17 increased in prevalence
over time. For example, TCGA-L5-A4OU exhibited a
marked increase in signature 17 among its late muta-
tions, accompanied by a decrease in signature 1A and
signature 5 (Fig. 5b, c).
Taken together, these results illustrate the utility of
deconstructSigs to reveal the mutational processes in
individual cancers, enabling comparisons of distinct
histologies within tumor types and the elucidation of
the dynamics of these mutational signatures over time.
Conclusions
Here we present a computational approach, deconstruct-
Sigs, which determines the composition of a given set of
mutational signatures in individual tumor specimens.
We have demonstrated that through using deconstruct-
Sigs we can consistently identify the same signatures of
mutational processes active in a single tumor sample
compared with the analysis of an entire sample set using
the WTSI Mutational Signature Framework [8]. We have
also shown some of the potential benefits of analyzing
samples on an individual basis, as a user can both detect
mutational processes active in only a small number of
samples and investigate well-established signatures without
having to consider or compile a large sample set. Fur-
thermore, we utilized this approach to consider how
the activity of mutational processes changes in individual
tumors over time.
Due to the recurrent nature of many mutational signa-
tures, present across multiple tumor types, there is much
interest in identifying these existing signatures in further
tumor samples. The input signature set, which by default
is the set of already published signatures, can also be a
user-defined parameter, so it is possible for it to be
adapted as mutational signatures are further identified and
refined through large-scale genomics analyses. For in-
stance, 30 signatures are now identified by the Wellcome
Trust Sanger Institute (http://cancer.sanger.ac.uk/cosmic/
signatures), some of which are identified in tumor types
not considered here, such as stomach cancer, kidney
clear cell carcinoma, and Hodgkin’s lymphoma. In future
studies and as new signatures are identified, these signa-
tures could be included in the input signatures set by the
user. Thus, we anticipate that deconstructSigs will com-
plement other efforts to define and identify mutational
processes.
Finally, as the sequencing of individual tumors becomes
increasingly common in a clinical setting, we expect
that the ability to determine contributions of specific
mutational processes within single samples will allow
for novel insights, revealing cancer vulnerabilities that
may guide clinical decision-making on a case-by-case
basis. It will be possible to identify potential environ-
mental exposures within individual tumors, which may
provide utility within a medico-legal setting. Finally,
this tool will enable the impact that previous therapies
have had on shaping the cancer genome to be defined
and further our understanding into the dynamic evolu-
tionary processes between primary and metastatic sites
within individual patients.
Availability of data and materials
The results published here are in part based on data
generated by TCGA project established by the National
Cancer Institute and National Human Genome Research
Institute. The data were retrieved through dbGaP
(Database of Genotypes and Phenotypes) authorization
(accession number phs000178.v9.p8). Information about
TCGA and the investigators and institutions that consti-
tute the TCGA research network can be found at http://
cancergenome.nih.gov/.
The multiregion sequencing data used can be found
in the European Genome-Phenome Archive (EGA,
https://www.ebi.ac.uk/ega/), under accession numbers
EGAS00001000840 and EGAS00001000809. The decon-
structSigs package (v1.6.0) is available on the Comprehen-
sive R Archive Network (CRAN, https://cran.r-project.org/)
(See figure on previous page.)
Fig. 5 Signatures present in esophageal carcinoma. a The signatures identified in a cohort of ESCA tumors by deconstructSigs, using the input
reference signatures from [4]. The prevalence, defined as the fraction of patients the signature was detected in, is plotted for each mutational
signature identified, and the proportion of patients with a higher fraction of early (red) or late (blue) mutations corresponding to that signature is
shown. b, c A specific analysis of two esophageal adenocarcinomas exhibiting signs of signature 17 activity. The mutational profiles are given for
all the mutations identified in both tumors, as well as the mutations classified as early or late. Signature 17 was identified as the largest contributor to
the early mutations of patient TCGA-2H-A9GR (b) whereas it was identified as the contributing to the generation of the majority of late mutations in
patient TCGA-L5-A4OU (c)
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under a GPL-2 license. It has also been deposited to
Zenodo (https://zenodo.org/) with a DOI (http://
dx.doi.org/10.5281/zenodo.45311).
Ethics approval
Ethics approval was not needed for this study.
Additional files
Additional file 1: Figure S1. Weights assigned to false positives and
false negatives in a randomly generated tumor cohort. A random cohort
of 500 tumors containing 2646 total signatures was generated with
known signature contributions of the published signatures. This cohort
was subjected to up to a ±5 % random perturbation to more accurately
reflect a ‘non-perfect’ theoretical tumor sample. Running deconstructSigs
on these simulated tumor samples resulted in some outputs containing
false positives, where a signature was erroneously identified as
contributing to the sample (a). The weights assigned to these false
positive results were seen almost uniformly have been under 6 % for
each signature (marked at the red line). b False negatives, where a
signature was erroneously rejected as contributing to the sample,
occurred 38 times from the analysis of the randomly simulated tumors
for a false negative rate of 1.4 %. The weights of all of the false negatives
were under 6 %, indicating that the use to this cutoff does not increase
the tendency of deconstructSigs to call false negatives. (PDF 111 kb)
Additional file 2: Supplementary methods, containing the specific
TCGA mutation files used in all analyses. (DOCX 86 kb)
Additional file 3: Table S1. The mutational signature contribution to
each TCGA tumor sample studied as determined by deconstructSigs and
WTSI Mutational Signature Framework. Signatures used as input to
deconstructSigs were limited to those extracted using the WTSI
Mutational Signature Framework approach. (TXT 464 kb)
Additional file 4: Figure S2. Comparison of the SSE between
deconstructSigs and WTSI Mutational Signatures Framework. a SSEs
between the input tumor mutational profile and reconstructed
mutational profile were calculated for each TCGA tumor analyzed. The
calculated SSEs from using the WTSI Mutational Signatures Framework
were compared with those from using deconstructSigs. Each point
represents the SSE as calculated through use of the signature weights
assigned by the WTSI Mutational Signatures Framework and the SSE
as calculated through the use of the signature weights assigned by
deconstructSigs. The SSE is consistent between the two approaches.
b Relationship between SSE and overall mutation count. As the
mutation count of the tumor sample increases, the calculated SSE
decreases. (PDF 632 kb)
Additional file 5: Figure S3. Comparison of signature contributions
between deconstructSigs and WTSI Mutational Signature Framework
using reference signatures. Cancer types with unambiguous signatures
extracted using WTSI Mutational Signatures Framework [8] were re-analyzed
with deconstructSigs and allowed to use any of the originally published
signatures [4]. For the signatures that were extracted using WTSI Mutational
Signature Framework, a comparison between the weights assigned by
deconstructSigs and those originally calculated by WTSI Mutational
Signatures Framework is plotted. A table of the values of all weights
assigned by deconstructSigs can be found in Table S2 (Additional file 6).
(PDF 321 kb)
Additional file 6: Table S2. The mutational signature contribution to
each TCGA tumor sample studied as determined by deconstructSigs and
WTSI Mutational Signature Framework. The full published set of
mutational signatures [4] was allowed to be used as input to
deconstructSigs. Tumor types considered were limited to those where
only unambiguous signatures could be extracted using the WTSI
Mutational Signature Framework to allow for direct comparison with the
input reference signature set. (TXT 359 kb)
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